Immunotargeting of antigen xCT attenuates stem-like cell behavior and metastatic progression in breast cancer

Cancer Research

Volumn 76, Issue 1, 2016, Pages 62-72

  Lanzardo, Stefania ^a   Conti, Laura ^a   Rooke, Ronald ^b   Ruiu, Roberto ^a   Accart, Nathalie ^c   Bolli, Elisabetta ^a   Arigoni, Maddalena ^a   Macagno, Marco ^a   Barrera, Giuseppina ^a   Pizzimenti, Stefania ^a   Aurisicchio, Luigi ^d   Calogero, Raffaele Adolfo ^a   Cavallo, Federica ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b ElsaLys Biotech   (France)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Takis Biotechnology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN XCT; CANCER VACCINE; DOXORUBICIN; OCTAMER TRANSCRIPTION FACTOR 4; REACTIVE OXYGEN METABOLITE; STEM CELL ANTIGEN 1; THY 1 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; AMINO ACID TRANSPORTER; CYSTINE; DNA VACCINE; GLUTAMIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN FUNCTION; ARTICLE; BREAST METASTASIS; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CELL FUNCTION; CELL SELF-RENEWAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOFLUOROMETRY; DNA IMMUNIZATION; DOSE RESPONSE; DOWN REGULATION; DRUG POTENTIATION; FEMALE; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEM LIKE CELL BEHAVIOR; TUMOR GROWTH; TUMOR REGRESSION; UPREGULATION; XCT GENE; 3T3 CELL LINE; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DISEASE COURSE; DRUG SCREENING; IMMUNOLOGY; KNOCKOUT MOUSE; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; SECONDARY; TUMOR CELL LINE;

AMINO ACID TRANSPORT SYSTEMS; ANIMALS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; CELL LINE, TUMOR; CYSTINE; DISEASE PROGRESSION; FEMALE; GLUTAMIC ACID; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEOPLASTIC STEM CELLS; NIH 3T3 CELLS; UP-REGULATION; VACCINES, DNA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84959020660     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1208     Document Type: Article

References (50)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62: 220-41.
2. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010;120:41-50.
3. Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Yet J, et al. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res 2012;72:1853-64.
4. Kwiatkowska-Borowczyk EP, Gabka-Buszek A, Jankowski J, Mackiewicz A. Immunotargeting of cancer stem cells. Contemp Oncol 2015;19:A52-9.
5. Aurisicchio L, Ciliberto G. Genetic cancer vaccines: current status and perspectives. Expert Opin Biol Ther 2012;12:1043-58.
6. Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E, et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000;165:5133-42.
7. Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, et al. The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal 2013;18:522-55.
8. Gout PW, Buckley AR, Simms CR, Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia 2001;15:1633-40.
9. Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, et al. Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci 2005;25:7101-10.
10. Narang VS, Pauletti GM, Gout PW, Buckley DJ, Buckley AR. Suppression of cystine uptake by sulfasalazine inhibits proliferation of human mammary carcinoma cells. Anticancer Res 2003;23:4571-9.
11. Doxsee DW, Gout PW, Kurita T, Lo M, Buckley AR, Wang Y, et al. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate 2007;67:162-71.
12. Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 2015;520: 57-62.
13. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011;19:387-400.
14. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 2013;24:450-65.
15. Chen RS, Song YM, Zhou ZY, Tong T, Li Y, Fu M, et al. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway. Oncogene 2009;28:599-609.
16. Huang Y, Dai Z, Barbacioru C, Sadee W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res 2005;65:7446-54.
17. Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E, et al. xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res 2013;73:1855-66.
18. Conti L, Lanzardo S, Arigoni M, Antonazzo R, Radaelli E, Cantarella D, et al. The noninflammatory role of high mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells. FASEB J 2013;27:4731-44.
19. Quaglino E, Mastini C, Amici A, Marchini C, Iezzi M, Lanzardo S, et al. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res 2010;70: 2604-12.
20. Donato MT, Martinez-Romero A, Jimenez N, Negro A, Herrera G, Castell JV, et al. Cytometric analysis for drug-induced steatosis in HepG2 cells. Chem Biol Interact 2009;181:417-23.
21. Fend L, Accart N, Kintz J, Cochin S, Reymann C, Le Pogam F, et al. Therapeutic effects of anti-CD115 monoclonal antibody in mouse cancer models through dual inhibition of tumor-associated macrophages and osteoclasts. PLoS One 2013;8:e73310.
22. Ravindranath V. Animal models and molecular markers for cerebral ischemia-reperfusion injury in brain. Methods Enzymol 1994;233:610-9.
23. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968; 25:192-205.
24. Nanni P, Landuzzi L, Nicoletti G, De Giovanni C, Rossi I, Croci S, et al. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J Immunol 2004;173: 2288-96.
25. Arigoni M, Barutello G, Lanzardo S, Longo D, Aime S, Curcio C, et al. A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors. Angiogenesis 2012;15:305-16.
26. Grange C, Lanzardo S, Cavallo F, Camussi G, Bussolati B. Sca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic mice. Neoplasia 2008;10:1433-43.
27. Riccardo F, Arigoni M, Buson G, Zago E, Iezzi M, Longo D, et al. Characterization of a genetic mouse model of lung cancer: a promise to identify non-small cell lung cancer therapeutic targets and biomarkers. BMC Genomics 2014;15 Suppl 3:S1.
28. Lo M, Wang YZ, Gout PW. The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol 2008;215:593-602.
29. Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 2008;15:413-48.
30. Schwitalla S. Tumor cell plasticity: the challenge to catch a moving target. J Gastroenterol 2014;49:618-27.
31. Kinoshita H, Okabe H, Beppu T, Chikamoto A, Hayashi H, Imai K, et al. Cystine/glutamic acid transporter is a novel marker for predicting poor survival in patients with hepatocellular carcinoma. Oncol Rep 2013; 29:685-9.
32. Sugano K, Maeda K, Ohtani H, Nagahara H, Shibutani M, Hirakawa K. Expression of xCT as a predictor of disease recurrence in patients with colorectal cancer. Anticancer Res 2015;35:677-82.
33. Singer E, Judkins J, Salomonis N, Matlaf L, Soteropoulos P, McAllister S, et al. Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma. Cell Death Dis 2015;6:e1601.
34. Sato A, Okada M, Shibuya K, Watanabe E, Seino S, Narita Y, et al. Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells. Stem Cell Res 2014; 12:119-31.
35. Shi X, Zhang Y, Zheng J, Pan J. Reactive oxygen species in cancer stem cells. Antioxid Redox Signal 2012;16:1215-28.
36. Ryoo IG, Choi BH, Kwak MK. Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells. Oncotarget 2015;6: 8167-84.
37. Mizuno T, Suzuki N, Makino H, Furui T, Morii E, Aoki H, et al. Cancer stemlike cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species. Gynecol Oncol 2015;137:299-305.
38. Linares V, Alonso V, Domingo JL. Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity. Expert Opin Drug Saf 2011;10: 253-63.
39. de la Fuente V, Federman N, Fustinana MS, Zalcman G, Romano A. Calcineurin phosphatase as a negative regulator of fear memory in hippocampus: control on nuclear factor-kappaB signaling in consolidation and reconsolidation. Hippocampus 2014;24:1549-61.
40. Dai L, Cao Y, Chen Y, Parsons C, Qin Z. Targeting xCT, a cystine-glutamate transporter induces apoptosis and tumor regression for KSHV/HIV-associated lymphoma. J Hematol Oncol 2014;7:30.
41. Robe PA, Martin DH, Nguyen-Khac MT, Artesi M, Deprez M, Albert A, et al. Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer 2009;9:372.
42. Aurisicchio L, Mancini R, Ciliberto G. Cancer vaccination by electro-genetransfer. Expert Rev Vaccines 2013;12:1127-37.
43. Rolla S, Nicolo C, Malinarich S, Orsini M, Forni G, Cavallo F, et al. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 2006;177:7626-33.
44. Liao WT, Ye YP, Deng YJ, Bian XW, Ding YQ. Metastatic cancer stem cells: from the concept to therapeutics. Am J Stem Cells 2014;3:46-62.
45. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005;2:3-14.
46. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010;70:68-77.
47. McCullagh EA, Featherstone DE. Behavioral characterization of system xcmutant mice. Behav Brain Res 2014;265:1-11.
48. Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 2004;3:294-300.
49. Narang VS, Pauletti GM, Gout PW, Buckley DJ, Buckley AR. Sulfasalazineinduced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of Doxorubicin. Chemotherapy 2007;53: 210-7.
50. Wang F, Yang Y. Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin. Breast Cancer Res Treat 2014;147:203-10.